Introduction: Coronary Artery Disease (CAD) remains a major problem worldwide. New and useful biomarkers for early diagnosis are necessary. MicroRNAs (miR) are short, non-coding RNAs that post transcriptionally regulate gene expression through degradation and translational repression of mRNAs.Aim: The current case-control study was designed to assess strength and relevance of diagnostic miR-126, 122 and Vascular Endothelial Growth Factor (VEGF) level in the diagnoses of angiographically proven CAD cases.Materials and Methods: Circulating levels of miR-126 and miR122 and VEGF levels were measured in serum from 100 middle aged 46-58 years patients with CAD and 100 patients without CAD through quantitative real-time polymerase chain reaction (qRT-PCR) analysis.Results: Circulating miR-122 level was significantly higher in CAD cases compared to control (1.60 +/- 1.06 and 0.93 +/- 0.43, p=0.001), however miR-126 was significantly lowered in CAD cases compared to control (0.82 +/- 0.51 and 1.01 +/- 0.47, p=0.02). Circulating VEGF level was significantly higher in CAD cases compared to control (182.97 +/- 156.49 and 105.49 +/- 103.88, p=0.02). Circulating miR-122, 126 and VEGF level did not show any association with demographic and clinical parameters. Area Under the Curve (AUC) for circulating miR-122, 126 and VEGF were 0.700, 0.644 and 0.649 with sensitivity and specificity of 66.67%, 56.41%, 61.18% and 70%, 60% and 64%, respectively. The combined diagnostic efficacy of miR- 122 and 126 showed higher sensitivity and specificity.Conclusion: Circulating miR-122 and 126 might be novel, noninvasive biomarkers for early diagnosis of CAD. Further exposition of the role of miR-122, 126 and VEGF in the progression of CAD will add to the understanding of the disease process leading to a new diagnostic approach. However, further studies on larger patient cohorts are required to validate the findings.
Ali, W., Mishra, S., Rizvi, A., Perrone, M., Tasleem, M., Wamique, M., et al. (2021). Diagnostic Value of Circulating MicroRNAs for Middle Aged Coronary Artery Disease Patients: A Case-control Study. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 15(3), 5-10 [10.7860/JCDR/2021/46116.14611].
Diagnostic Value of Circulating MicroRNAs for Middle Aged Coronary Artery Disease Patients: A Case-control Study
Perrone, MA;
2021-03-01
Abstract
Introduction: Coronary Artery Disease (CAD) remains a major problem worldwide. New and useful biomarkers for early diagnosis are necessary. MicroRNAs (miR) are short, non-coding RNAs that post transcriptionally regulate gene expression through degradation and translational repression of mRNAs.Aim: The current case-control study was designed to assess strength and relevance of diagnostic miR-126, 122 and Vascular Endothelial Growth Factor (VEGF) level in the diagnoses of angiographically proven CAD cases.Materials and Methods: Circulating levels of miR-126 and miR122 and VEGF levels were measured in serum from 100 middle aged 46-58 years patients with CAD and 100 patients without CAD through quantitative real-time polymerase chain reaction (qRT-PCR) analysis.Results: Circulating miR-122 level was significantly higher in CAD cases compared to control (1.60 +/- 1.06 and 0.93 +/- 0.43, p=0.001), however miR-126 was significantly lowered in CAD cases compared to control (0.82 +/- 0.51 and 1.01 +/- 0.47, p=0.02). Circulating VEGF level was significantly higher in CAD cases compared to control (182.97 +/- 156.49 and 105.49 +/- 103.88, p=0.02). Circulating miR-122, 126 and VEGF level did not show any association with demographic and clinical parameters. Area Under the Curve (AUC) for circulating miR-122, 126 and VEGF were 0.700, 0.644 and 0.649 with sensitivity and specificity of 66.67%, 56.41%, 61.18% and 70%, 60% and 64%, respectively. The combined diagnostic efficacy of miR- 122 and 126 showed higher sensitivity and specificity.Conclusion: Circulating miR-122 and 126 might be novel, noninvasive biomarkers for early diagnosis of CAD. Further exposition of the role of miR-122, 126 and VEGF in the progression of CAD will add to the understanding of the disease process leading to a new diagnostic approach. However, further studies on larger patient cohorts are required to validate the findings.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.